论文部分内容阅读
丝裂霉素C 微囊(MMC-mc)动脉内给药治疗肿瘤患者时,由于在动脉内可形成机械性栓塞而延长药物的接触作用,故具有潜在的治疗效益。给6例(结肠直肠3例,头颈部2例,胰腺1例)肿瘤患者动脉内灌注MMC-mc。每间隔4周,接受1或2个治疗周期。注射药物前后均作血管造影术以作比较。MMC 的乙基纤维素微囊中的活性MMC 含量为45%(W/W),平均粒径200μm(150～250)。MMC-mc 动脉内给药后24 h 内,于10个间隔点取血样1 ml,以甲醇处理,离心,上清液在氮气下于40~C℃干燥。残留部份溶于300 μl 缓冲液中,取100 μl 试验。按Pinedo 等的方法和条件进行层析。
Mitomycin C microcapsules (MMC-mc) intra-arterial administration of tumor patients, due to the formation of mechanical embolization in the artery to prolong the contact effect of the drug, it has potential therapeutic benefits. Six patients (3 in colorectum, 2 in head and neck, and 1 in pancreas) were intra-arterially infused with MMC-mc. Every 4 weeks, receive 1 or 2 treatment cycles. Before and after injection of drugs for angiography for comparison. The active MMC content of MMC in ethylcellulose microcapsules is 45% (W / W) and the average particle size is 200μm (150 ~ 250). Within 24 h after intra-arterial MMC-mc administration, 1 ml of blood was taken at 10 intervals and treated with methanol, centrifuged, and the supernatant was dried under nitrogen at 40 to C ° C. Residues were dissolved in 300 μl buffer, 100 μl test. Chromatography was performed according to the method and conditions of Pinedo et al.